LYFNUA

This brand name is authorized in Estonia, Croatia, Ireland, Italy, Japan, Lithuania

Active ingredients

The drug LYFNUA contains one active pharmaceutical ingredient (API):

1 Gefapixant UNII DFK0FC2VVV - GEFAPIXANT CITRATE

Gefapixant is a selective antagonist of the P2X3 receptor. P2X3 receptors are ATP-gated ion channels found on sensory C fibres of the vagus nerve in the airways. C fibres are activated in response to inflammation or chemical irritants. Blockade of ATP signalling through P2X3 receptors reduces excessive sensory-nerve activation and excessive cough induced by extracellular ATP. Read about Gefapixant

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
LYFNUA Film-coated tablet	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
R05DB29		R Respiratory system → R05 Cough and cold preparations → R05D Cough suppressants, excl. combinations with expectorants → R05DB Other cough suppressants
Discover more medicines within R05DB29

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 3046328, 3046339, 3046340, 3046351
Country: IT	Agenzia del Farmaco	Identifier(s): 050897014, 050897026, 050897038, 050897040
Country: JP	医薬品医療機器総合機構	Identifier(s): 2290001F1028
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1097792, 1097793, 1097794, 1097795